“…METHODS: This retrospective study included consecutive adult patients with laboratory-confirmed SARS-CoV-2 infection who received ECMO for ARDS in 21 experienced ECMO centres in eight European countries (Austria, Belgium, England, France, Germany, Italy, Portugal, and Spain) between Jan 1, 2020, and Sept 30, 2021. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…</p> <p><u>Biography</u></p> <p>1959: &Eacute;cole normale sup&eacute;rieure (Ulm) in Paris<br /> 1963: Agr&eacute;gation de physique<br /> 1967: Doctoral thesis in LAL Orsay<br /> 1968 &ndash; 1969 experiments on e+e&ndash; colliding ring ACO in LAL, France<br /> 1969: Ma&icirc;tre de recherche in CNRS<br /> 1976: Indefinite appointment at CERN (research physicist)<br /> 1969 &ndash; 1973: Experiments at CERN PS<br /> 1972 &ndash; 1978: Experiments at Omega Spectrometer- Physics Coordinator of the Omega Spectrometer<br /> 1978 &ndash; 1986: Spokesman of the NA14 and NA14-2 experiments<br /> 1979 onwards: Participation to the conception and realization of the Delphi 
experiment at LEP 1990: Leader of Delphi CERN Group<br /> 1996 &ndash; 1997: Spokesman of Delphi<br /> 1998 &ndash; 2000: Coordinator of Delphi LEP200 physics<br /> 2000 onwards: Member of the LHC experiment CMS&nbsp;</p> <p>Plenary Rapporteur Talks at six major International Conferences
Lectures in many Physics Schools and Workshops
Member of scientific and evaluation committees (CERN, DESY (Germany), Portugal, Canada, Spain, France, Belgium, Sweden)
2004-2007 Chair of the IN2P3 Conseil Scientifique, France
Plenary Talks for non-specialized audiences (UTLS 2000, EPS 2002, CERN 50 years 2004)
About 850 publications in referenced journals
Doctor Honoris Causa of Stockholm University in 1996.…”
Enlace del recurso

“…METHODS: FOXFIRE, SIRFLOX, and FOXFIRE-Global were randomised, phase 3 trials done in hospitals and specialist liver centres in 14 countries worldwide (Australia, Belgium, France, Germany, Israel, Italy, New Zealand, Portugal, South Korea, Singapore, Spain, Taiwan, the UK, and the USA). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…METHODS: In this double-blind, single-centre phase 1 trial, we isolated participants in a purpose-built containment facility at the University of Antwerp Hospital (Antwerp, Belgium), to minimise the risk of environmental release of the novel OPV2 candidates. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…The OCAC dataset comprises 63 genotyping project/case–control sets with participants of European ancestry recruited from 14 countries (US, Australia, Belarus, Germany, Belgium, Denmark, Finland, Norway, Canada, Poland, UK, Spain, Netherlands, and Sweden). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Given the current decline of the COVID-19 pandemic in Belgium, it is difficult to anticipate the rate of participant recruitment. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…METHODS: We did two randomised studies at two centres in Belgium. The first was a phase 4 historical control study of monovalent OPV2 in Antwerp, done before global withdrawal of OPV2, and the second was a phase 2 study in Antwerp and Ghent with novel OPV2-c1 and novel OPV2-c2. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…METHODS: DisCoVeRy was a phase 3, open-label, adaptive, multicentre, randomised, controlled trial conducted in 48 sites in Europe (France, Belgium, Austria, Portugal, Luxembourg). Adult patients (aged ≥18 years) admitted to hospital with laboratory-confirmed SARS-CoV-2 infection and illness of any duration were eligible if they had clinical evidence of hypoxaemic pneumonia, or required oxygen supplementation. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…METHODS: In this prospective population study, we used data from participants in the Flemish Study on Environment, Genes and Health Outcomes (FLEMENGHO), done in northern Belgium from 1985 to 2019, and invited participants to a follow-up examination in 2005–10. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…METHODS: This ongoing phase 2 and 3 double-blind, placebo-controlled trial was done in adults aged 18 years and older who were in good health or with a stable chronic health condition, at 31 sites in five countries (Belgium, Brazil, Colombia, Philippines, and South Africa). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…C.S. received a research grant from FWO, Belgium, not related to the submitted work. I.S. declared being a Co-founder of IVFvision Ltd, UK. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Since October 2015, T.D’.H has left Leuven University Hospital Gasthuisberg, but continues to serve as Professor in Reproductive Medicine and Biology at KU Leuven (University of Leuven) Belgium and at the Dept of Obstetrics, Gynecology and Reproduction at Yale University, New Haven, USA. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…F.J.M.B. received monetary compensation as a member of the external advisory board for Merck Serono (the Netherlands) and Ferring Pharmaceuticals BV (the Netherlands) for advisory work for Gedeon Richter (Belgium) and Roche Diagnostics on automated AMH assay development, and for a research cooperation with Ansh Labs (USA). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Validation: The biometric accuracy was assessed by measuring eight anatomic distances: (1) Maximum craniocaudal aperture of the right orbit. (2) Maximum craniocaudal aperture of the left orbit. (3) Maximum height of the mandible from chin point in the midline. (4) Maximum cranial length (5) Maximum cranial width. (6) Maximum height of piriform aperture. (7) Distance between lateral most aspect of mandibular condyles. (8) Distance between lateral most aspect of posterior hard palate in both CT- and MRI-based 3D renderings of the human cadaveric skull using Mimics software (Materialise(®), Ghent, Belgium). These distances were compared with those directly measured on the cadaveric skull. …”
Enlace del recurso
Enlace del recurso

“…Given the current decline of the COVID-19 pandemic in Belgium, it is difficult to anticipate the rate of participant recruitment. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…METHODS: Organisms were consecutively collected (1/patient) from 79 medical centers located in the US (n=12,748; 35 centers), western EU (W-EU; n=12,198; 29 centers from 10 nations: Belgium, France, Germany, Ireland, Italy, Portugal, Spain, Sweden, Switzerland, and the United Kingdom), and eastern EU (E-EU; n=3,297; 15 centers from 12 nations: Belarus, Croatia, Czech Republic, Greece, Hungary, Israel, Poland, Romania, Russia, Slovakia, Slovenia, and Turkey). …”
Enlace del recurso
Enlace del recurso

“…Computed tomography (CT) images of the specimens were obtained, and three-dimensional (3D) point cloud models of the trochleae were then created and exported using a medical segmentation software program (Mimics, Materialise Inc., Leuven, Belgium). Circular defect models were created virtually in each point-cloud model of the recipient trochlea at both supero-lateral (18 mm and 22.5 mm) and central (18 mm, 22.5 mm, 30 mm) locations (Figure 1A). …”
Enlace del recurso
Enlace del recurso

“…Participants were randomly assigned (1:1:1:1:1:1), using permutated block sizes of 12, 18, and 24, to one, two, or three doses of the 2-valent vaccine (Cervarix, GSK Biologicals, Rixensart, Belgium) or the 9-valent vaccine (Gardasil 9, Sanofi Pasteur MSD, Lyon, France). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Broekmans reports personal fees as Member of the external advisory board for Ferring BV, The Netherlands, personal fees as Member of the external advisory board for Merck Serono, The Netherlands, personal fees as Member of the external advisory for Gedeon Richter, Belgium, personal fees from Educational activities for Ferring BV, The Netherlands, grants from Research support grant Merck Serono, grants from Research support grant Ferring, personal fees from Advisory and consultancy work Roche, outside the submitted work. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…F.J.M.B. receives monetary compensation as a member of the external advisory board for Merck Serono (the Netherlands), Ferring Pharmaceutics BV (the Netherlands) and Gedeon Richter (Belgium), he receives personal fees from educational activities for Ferring BV (the Netherlands) and for advisory and consultancy work for Roche and he receives research support grants from Merck Serono and Ferring Pharmaceutics BV, outside the submitted work. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso